Anti-inflammatory compositions and methods
AssigneeSearete LLC, a limited liability corporation of the State of Delaware
InventorsRoderick A. Hyde, Stephen L. Malaska, Elizabeth A. Sweeney, Lowell L. Wood, JR.
Life of this patent
Estimating the term…
Abstract
Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that modulate at least one inflammatory response or reaction. According to various embodiments, the compositions, methods, devices, and systems relate to modulating one or more of Toll-like receptors, Src family kinases, NF-kB molecules, proteases, or proteasomes.
Claims77
A therapeutic composition, comprising:
- at least one first agent configured to modulate the activity of one or more Toll-like receptors;
- at least one second agent configured to modulate the activity of one or more NF-κB molecules;
- and
- at least one pharmaceutically-acceptable carrier or excipient.
-4. (canceled)
(canceled)
-10. (canceled)
-15. (canceled)
-23. (canceled)
-26. (canceled)
(canceled)
(canceled)
-42. (canceled)
-46. (canceled)
-49. (canceled)
-54. (canceled)
A therapeutic composition comprising:
- at least one of chloroquine, M62812, or quinine;
- at least one of disulfiram, ditiocarb, sulindac, sulfasalazine, or bortezomib;
- and
- at least one pharmaceutically-acceptable carrier or excipient.
(canceled)
A method of modulating at least one immune response of one or more cells of a subject, comprising:
- administering to the subject an effective amount of at least one therapeutic composition, including
- at least one first agent configured to modulate the activity of one or more Toll-like receptors;
- at least one second agent configured to modulate the activity of one or more NF-kB molecules;
- and
- at least one pharmaceutically-acceptable carrier or excipient.
-63. (canceled)
-69. (canceled)
-74. (canceled)
-82. (canceled)
(canceled)
-102. (canceled)
-106. (canceled)
-109. (canceled)
-131. (canceled)
A method of modulating the activity of one or more Toll-like receptors and one or more NF-kB molecules of a subject, comprising:
- administering to the subject an effective amount of at least one therapeutic composition, including at least one first agent configured to modulate the activity of one or more Toll-like receptors,
- at least one second agent configured to modulate the activity of one or more NF-kB molecules;
- and
- at least one pharmaceutically-acceptable carrier or excipient.
-134. (canceled)
-140. (canceled)
-145. (canceled)
-153. (canceled)
(canceled)
-173. (canceled)
-177. (canceled)
-180. (canceled)
-208. (canceled)
A method of treating a subject afflicted with or suspected of being afflicted with malaria, comprising:
- administering to a subject an effective amount of at least one therapeutic composition, including
- at least one of chloroquine, M62812, or quinine;
- at least one of disulfiram, ditiocarb, sulindac, sulfasalazine, or bortezomib;
- and
- at least one pharmaceutically-acceptable carrier or excipient.
-215. (canceled)
Dependencies are inferred from the claim text.